Loading
38 biomarkers and alterations against 474 cancers: 2594 filled cells covering 443 products. Each cell counts matched products approved in your region against those still in trials; the tumour board answers one profile, this is the whole grid. Change region in the header.
The same matcher as the tumour board scores every product, technology and trial against one biomarker (target match 3, glossary-term match 2, technology match 2, tag match 1). Each hit is then placed in every cancer column the graph links it to, directly or through its products. A product is “approved” in a cell when the regional approvals table records approval or conditional approval for your region; where we hold no regional record, the corpus status (usually the FDA) is used and the tooltip says so.
Approval in a cell means the product is approved somewhere in that cancer, not necessarily for that biomarker-defined subgroup; a PD-1 antibody approved for lung cancer will appear in the PD-L1 row for every cancer it is approved in. Withdrawn, negative and historic records are excluded. Counts are a map of what the corpus documents, not a treatment recommendation. Click through to the tumour board to see the products, cautions and trials behind a cell.